Appeal No. 1996-1005
Application 07/947,982
67. A polynucleotide molecule, comprising:
(a) a first polynucleotide molecule coding for a tRNA; and
(b) a second polynucleotide molecule coding for a ribozyme, said second
polynucleotide molecule being located between the A- and B-boxes of said first
polynucleotide molecule.
96. A pharmaceutical preparation, comprising as an active component one or
more of the polynucleotide molecules of claim 67.
The references relied upon by the examiner are:
Pardridge et al. (Pardridge) 4,902,505 Feb. 20, 1990
Hofstetter et al. (Hofstetter), “A Split Promoter for a Eucaryotic tRNA Gene,” Cell, Vol. 24,
pp. 573-85 (May 1981)
Jennings et al. (Jennings), “Inhibition of SV40 replicon function by engineered antisense
tRNA transcribed by RNA polymerase III,” The EMBO Journal, Vol. 6, No. 10, pp. 3043-46
(1987).
Wu et al. (Wu 1987), “Receptor-mediated in Vitro Gene Transformation by a Soluble DNA
Carrier System,” The Journal of Biological Chemistry, Vol. 262, No. 10, pp. 4429-32 (Apr.
1987).
Uhlenbeck, “A small catalytic oligoribonucleotide,” Nature, Vol. 328, pp. 596-600 (Aug. 1987).
Wu et al. (Wu 1988), “Receptor-mediated Gene Delivery and Expression in Vitro,” The
Journal of Biological Chemistry, Vol. 263, No. 29, pp. 14621-624 (Oct. 1988).
Haseloff et al. (Haseloff), “Simple RNA enzymes with new and highly specific
endoribonuclease activities,” Nature, Vol. 334, pp. 585-91 (Aug. 1988).
Simons, “Naturally occurring antisense RNA control -- a brief review,” GENE, Vol. 72, pp.
35-44 (1988).
Claims 67, 69, 71, 73 through 76, 79, 80, 96, 97 and 99 are rejected under 35 U.S.C. §
103. As evidence of obviousness, the examiner relies upon Jennings, Hofstetter, Wu 1987,
Wu 1988, Uhlenbeck and Haseloff. Claims 77 and 78 stand rejected under 35 U.S.C. § 103.
In addition to the evidence of obviousness set forth in the previous sentence, the examiner
2
Page: Previous 1 2 3 4 5 6 Next
Last modified: November 3, 2007